vs
Essent Group Ltd.（ESNT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Essent Group Ltd.的季度营收约是Orthofix Medical Inc.的1.4倍（$312.4M vs $219.9M），Essent Group Ltd.净利率更高（49.6% vs -1.0%，领先50.6%），Orthofix Medical Inc.同比增速更快（2.0% vs -0.8%），Essent Group Ltd.自由现金流更多（$848.7M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
Essentra PLC是一家面向全球市场的塑料及纤维产品供应商，总部位于英国牛津郡基德灵顿，业务网络覆盖全球多个区域，目前在伦敦证券交易所上市，可面向各行业客户提供多元化的相关产品及配套服务，在所属细分领域拥有较高的市场认可度。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ESNT vs OFIX — 直观对比
营收规模更大
ESNT
是对方的1.4倍
$219.9M
营收增速更快
OFIX
高出2.8%
-0.8%
净利率更高
ESNT
高出50.6%
-1.0%
自由现金流更多
ESNT
多$831.9M
$16.8M
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.4M | $219.9M |
| 净利润 | $155.0M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 59.1% | 0.2% |
| 净利率 | 49.6% | -1.0% |
| 营收同比 | -0.8% | 2.0% |
| 净利润同比 | -7.7% | 92.4% |
| 每股收益（稀释后） | $1.61 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESNTOFIX
| Q4 25 | $312.4M | $219.9M | ||
| Q3 25 | $311.8M | $205.6M | ||
| Q2 25 | $319.1M | $203.1M | ||
| Q1 25 | $317.6M | $193.6M | ||
| Q4 24 | $315.0M | $215.7M | ||
| Q3 24 | $316.6M | $196.6M | ||
| Q2 24 | $312.9M | $198.6M | ||
| Q1 24 | $298.4M | $188.6M |
净利润ESNTOFIX
| Q4 25 | $155.0M | $-2.2M | ||
| Q3 25 | $164.2M | $-22.8M | ||
| Q2 25 | $195.3M | $-14.1M | ||
| Q1 25 | $175.4M | $-53.1M | ||
| Q4 24 | $167.9M | $-29.1M | ||
| Q3 24 | $176.2M | $-27.4M | ||
| Q2 24 | $203.6M | $-33.4M | ||
| Q1 24 | $181.7M | $-36.0M |
毛利率ESNTOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率ESNTOFIX
| Q4 25 | 59.1% | 0.2% | ||
| Q3 25 | 63.9% | -8.3% | ||
| Q2 25 | 72.4% | -7.9% | ||
| Q1 25 | 65.2% | -25.2% | ||
| Q4 24 | 61.9% | -5.3% | ||
| Q3 24 | 65.6% | -9.6% | ||
| Q2 24 | 76.4% | -12.5% | ||
| Q1 24 | 71.6% | -15.6% |
净利率ESNTOFIX
| Q4 25 | 49.6% | -1.0% | ||
| Q3 25 | 52.7% | -11.1% | ||
| Q2 25 | 61.2% | -6.9% | ||
| Q1 25 | 55.2% | -27.4% | ||
| Q4 24 | 53.3% | -13.5% | ||
| Q3 24 | 55.6% | -13.9% | ||
| Q2 24 | 65.1% | -16.8% | ||
| Q1 24 | 60.9% | -19.1% |
每股收益（稀释后）ESNTOFIX
| Q4 25 | $1.61 | $-0.05 | ||
| Q3 25 | $1.67 | $-0.57 | ||
| Q2 25 | $1.93 | $-0.36 | ||
| Q1 25 | $1.69 | $-1.35 | ||
| Q4 24 | $1.59 | $-0.76 | ||
| Q3 24 | $1.65 | $-0.71 | ||
| Q2 24 | $1.91 | $-0.88 | ||
| Q1 24 | $1.70 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.8B | $450.0M |
| 总资产 | $7.4B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESNTOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务ESNTOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益ESNTOFIX
| Q4 25 | $5.8B | $450.0M | ||
| Q3 25 | $5.7B | $442.5M | ||
| Q2 25 | $5.7B | $458.3M | ||
| Q1 25 | $5.7B | $458.3M | ||
| Q4 24 | $5.6B | $503.1M | ||
| Q3 24 | $5.6B | $525.9M | ||
| Q2 24 | $5.4B | $546.0M | ||
| Q1 24 | $5.2B | $570.3M |
总资产ESNTOFIX
| Q4 25 | $7.4B | $850.6M | ||
| Q3 25 | $7.4B | $832.6M | ||
| Q2 25 | $7.2B | $837.2M | ||
| Q1 25 | $7.2B | $823.1M | ||
| Q4 24 | $7.1B | $893.3M | ||
| Q3 24 | $7.1B | $867.9M | ||
| Q2 24 | $6.7B | $882.0M | ||
| Q1 24 | $6.6B | $906.0M |
负债/权益比ESNTOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $856.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $848.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 271.7% | 7.6% |
| 资本支出强度资本支出/营收 | 2.4% | 4.9% |
| 现金转化率经营现金流/净利润 | 5.52× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ESNTOFIX
| Q4 25 | $856.1M | $27.7M | ||
| Q3 25 | $215.9M | $12.4M | ||
| Q2 25 | $189.5M | $11.6M | ||
| Q1 25 | $221.6M | $-18.4M | ||
| Q4 24 | $861.5M | $23.7M | ||
| Q3 24 | $229.2M | $11.7M | ||
| Q2 24 | $188.7M | $9.0M | ||
| Q1 24 | $216.9M | $-18.6M |
自由现金流ESNTOFIX
| Q4 25 | $848.7M | $16.8M | ||
| Q3 25 | $210.6M | $2.5M | ||
| Q2 25 | $188.8M | $4.5M | ||
| Q1 25 | $221.3M | $-25.1M | ||
| Q4 24 | $854.8M | $15.2M | ||
| Q3 24 | $228.7M | $6.3M | ||
| Q2 24 | $187.6M | $-360.0K | ||
| Q1 24 | $212.5M | $-29.1M |
自由现金流率ESNTOFIX
| Q4 25 | 271.7% | 7.6% | ||
| Q3 25 | 67.5% | 1.2% | ||
| Q2 25 | 59.2% | 2.2% | ||
| Q1 25 | 69.7% | -13.0% | ||
| Q4 24 | 271.3% | 7.0% | ||
| Q3 24 | 72.2% | 3.2% | ||
| Q2 24 | 60.0% | -0.2% | ||
| Q1 24 | 71.2% | -15.4% |
资本支出强度ESNTOFIX
| Q4 25 | 2.4% | 4.9% | ||
| Q3 25 | 1.7% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 2.1% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 1.5% | 5.6% |
现金转化率ESNTOFIX
| Q4 25 | 5.52× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 5.13× | — | ||
| Q3 24 | 1.30× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 1.19× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
